Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9059MR)

This product GTTS-WQ9059MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9059MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1772MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ11816MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ5740MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ7197MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ5827MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ5713MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ818MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ7898MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-249320
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW